-
ORAL, DISEASE-MODIFYING SMALL MOLECULE INHIBITORS OF PROTEIN SELF-ASSOCIATION FOR NEURODEGENERATION
Breaking News:
Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer’s Patients•NanoDetection Technology™ and Oligomerix™ Announce Exclusive Global Licensing Agreement for Breakthrough | Neurodegenerative Diagnostic Antibodies•
Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer’s Patients•NanoDetection Technology™ and Oligomerix™ Announce Exclusive Global Licensing Agreement for Breakthrough | Neurodegenerative Diagnostic Antibodies•
About Oligomerix
Oligomerix, Inc., is a privately held clinical stage biotechnology company pioneering the development of disease-modifying, oral small molecule therapeutics targeting protein aggregation in Alzheimer’s disease and rare neurodegenerative diseases such as progressive supranuclear palsy (PSP).
Technology
Oligomerix’s lead candidate is a small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade and its progression.
Pipeline
Oligomerix’s platform includes our lead compound (OLX07010) and 2nd generation series of compounds.
